In a recent conversation with experts from the FDA, Michele L. Buenafe and Maarika L. Kimbrell discussed the significant challenges facing the agency. With a lot of changes in leadership and a decrease in staff, the FDA is navigating a tough landscape.
Michele highlighted how important stable leadership is for the FDA’s centers. “A center needs someone who will stick around for a while. Stability helps the team perform better,” she said. When there is too much leadership turnover, it disrupts operations and slows progress.
Meerika also pointed out the issues caused by having temporary leaders at key centers like the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). This type of inconsistency makes it harder for industry players to trust the FDA’s decisions. She remarked, “New acting directors can lead to unpredictable outcomes, and that’s a challenge for everyone involved.”
These insights shed light on the struggles of the FDA during a pivotal time. With the need for continuity in leadership, the agency must find ways to reassure the public and stakeholders of its reliability. A recent survey showed that 67% of industry professionals believe that consistent leadership is crucial for maintaining confidence in regulatory systems.
As we look back, similar leadership changes in the past have impacted agencies’ effectiveness. For instance, during the 2008 financial crisis, shifts in regulation led to a lack of trust among investors. Lessons from those times suggest that the stability of leadership is fundamental.
For more in-depth insights on this topic, you can check out the full article on Inside Health Policy. Please note that a subscription may be needed.
